Peter Anastasiou, Capsida CEO

Cap­si­da makes $55M deal with Eli Lil­ly to de­vel­op gene ther­a­pies

Cap­si­da Bio­ther­a­peu­tics has added an­oth­er Big Phar­ma part­ner for its gene ther­a­py plat­form, strik­ing a deal with Eli Lil­ly to de­vel­op ther­a­pies for cen­tral ner­vous sys­tem dis­eases.

Eli Lil­ly will pay $55 mil­lion up­front, in cash plus a com­mit­ment to join a fu­ture fundraise. Cap­si­da will be el­i­gi­ble for $685 mil­lion in mile­stone pay­ments, plus roy­al­ties. Cap­si­da will al­so get the op­tion to join in on de­vel­op­ment and com­mer­cial­iza­tion of one prod­uct un­der the agree­ment, in ex­change for a share of prof­its.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.